Vertex Pharmaceuticals (VRTX) Stock Price
Vertex Pharmaceuticals Price
Over the last 19 years Vertex Pharmaceuticals grew revenue by 23.6% annually, reaching 12.07 B USD. Earnings per share have grown at 40.3% per year over the last 14 years. For Vertex Pharmaceuticals, the net margin of 32.7% is up versus 30.9% a few years ago. The consensus 12-month price target for Vertex Pharmaceuticals is 580.00 USD, about 15.1% above where the stock trades today. Of 36 analysts, 29 rate the stock a buy — an overall Buy consensus.
Vertex Pharmaceuticals stock price
Vertex Pharmaceuticals business model & stock analysis
Frequently asked questions about Vertex Pharmaceuticals
The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.
Vertex Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Vertex Pharmaceuticals Inc in the market include companies like Amgen, Gilead Sciences, and Bristol-Myers Squibb.
Vertex Pharmaceuticals Inc. is a renowned biotechnology company based in Boston, Massachusetts. Founded in 1989, Vertex has emerged as a global leader in developing innovative therapies for serious medical conditions. The company focuses on discovering transformative medicines for diseases including cystic fibrosis, pain, and other debilitating illnesses. Vertex has an esteemed track record of successful breakthroughs, with several FDA-approved drugs in its portfolio. With a strong commitment to research and development, Vertex Pharmaceuticals Inc. continues to pioneer advancements in the field of biotechnology, striving to improve the lives of countless patients worldwide.
Vertex Pharmaceuticals Inc. has achieved several significant milestones throughout its history. One of the most notable achievements is the development of breakthrough treatments for cystic fibrosis (CF). The company successfully introduced the first-ever CF medicine targeting the underlying cause of the disease, known as Kalydeco. Vertex Pharmaceuticals Inc. also made remarkable progress with other CF treatments like Orkambi, Symdeko, and Trikafta, significantly improving the lives of CF patients worldwide. Additionally, the company has expanded its pipeline with innovative therapies, focusing on various diseases including cancer, pain, and genetic disorders. These remarkable milestones highlight Vertex Pharmaceuticals Inc.'s commitment to revolutionize medical treatments and improve patient outcomes.
Vertex Pharmaceuticals Inc is primarily present in several countries and regions. The company has a strong presence in the United States where it is headquartered, with its main facilities and operations located there. Additionally, Vertex Pharmaceuticals Inc has expanded its presence internationally. The company has a significant presence in Europe, including countries such as Germany, France, Italy, and the United Kingdom. Furthermore, Vertex Pharmaceuticals Inc has established operations in Canada and several other countries. With its global reach, Vertex Pharmaceuticals Inc aims to provide innovative pharmaceutical solutions to patients worldwide.
Vertex Pharmaceuticals Inc represents values such as innovation, scientific excellence, and patient-focused approach. The company is committed to discovering transformative medicines to benefit people with serious diseases, with a particular focus on diseases such as cystic fibrosis. Vertex Pharmaceuticals Inc prioritizes research and development, leveraging cutting-edge technologies and expertise to advance their pipeline. With a culture of collaboration and a strong sense of purpose, Vertex Pharmaceuticals Inc aims to make a meaningful impact on patients' lives. By combining scientific expertise and a patient-centric approach, the company is dedicated to improving the quality of life and outcomes for those in need.
Analysts currently set an average price target of 553.08 USD for the Vertex Pharmaceuticals stock (median: 580.00 USD), implying +9.6 % versus the latest price. The consensus is based on 36 analyst ratings.
36 analysts currently rate the Vertex Pharmaceuticals stock: 29 recommend buying, 6 holding and 1 selling. For 2026, analysts expect Vertex Pharmaceuticals to generate revenue of 13.23 B USD and earnings per share of 18.49 USD.
Converted at the current exchange rate, the Vertex Pharmaceuticals share trades at 448.00 EUR (504.00 USD).
The Vertex Pharmaceuticals share (VRTX) is listed on 11 stock exchanges, including: NASDAQ (VRTX), London (0QZU.L), SIX (Zürich) (VRTX.SW), XETRA (VX1.DE), Frankfurt (VX1.F), München (VX1.MU), Düsseldorf (VX1.DU), Hamburg (VX1.HM).
Vertex Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA.
The expected revenue of Vertex Pharmaceuticals is 13.23 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Vertex Pharmaceuticals is 4.74 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Vertex Pharmaceuticals is currently 27.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vertex Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Vertex Pharmaceuticals is currently 9.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vertex Pharmaceuticals stock.
The Eulerpool Quality Score for Vertex Pharmaceuticals is 5/10.
The ISIN of Vertex Pharmaceuticals is US92532F1003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Vertex Pharmaceuticals is 882807. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Vertex Pharmaceuticals is VRTX. The ticker symbol is used to trade Vertex Pharmaceuticals shares on the stock exchange.
Vertex Pharmaceuticals stock
Vertex Pharmaceuticals Peer Group
Vertex Pharmaceuticals Ticker
Vertex Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Vertex Pharmaceuticals
Our stock analysis for Vertex Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vertex Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.